Now, people who wish to lose weight with a glucagon-like peptide-1 receptor agonist, also known as GLP-1 RAs or GLP-1 medications, have a new, needle-free option
After hearing anecdotes of patients on the diabetes and obesity drugs experiencing nonarteritic anterior ischemic optic neuropathy, or NAION, researchers at Massachusetts Eye and Ear analyzed data from a registry of patients at their institution to see if there was a broad trend
With only 3 mg of caffeine per capsule, this formula delivers clean energy without overstimulation, making it suitable for those sensitive to stimulants or seeking a supplement that can be taken at any time of day
While each peptide has been investigated independently in laboratory settings, blended research products are selected based on the objectives of a particular study rather than any established therapeutic application
Published Tuesday in the journal Cell Metabolism, the study is the latest research to come out of the laboratory of Daniel Drucker, the Canadian scientist renowned for his pioneering research into glucagon-like peptide-1 receptor agonists, or GLP-1s
For questions about your dose or results, consult your provider
